Glabridin arrests cell cycle and inhibits proliferation of hepatocellular carcinoma by suppressing braf/MEK signaling pathway

Glabridin inhibits migration and invasion by transcriptional inhibition of matrix metalloproteinase 9 through modulation of NF-κB and AP-1 activity in human liver cancer cells

(2014) Ming-Ju Hsieh et al.   BRITISH JOURNAL OF PHARMACOLOGY

Targeting tumour-supportive cellular machineries in anticancer drug development

(2014) Matthias Dobbelstein et al.   NATURE REVIEWS DRUG DISCOVERY

Glabridin Mediate Caspases Activation and Induces Apoptosis through JNK1/2 and p38 MAPK Pathway in Human Promyelocytic Leukemia Cells

(2014) Hsin-Lien Huang et al.   PLoS One

Targeting of magnolin on ERKs inhibits Ras/ERKs/RSK2-signaling-mediated neoplastic cell transformation

(2013) Cheol-Jung Lee et al.   CARCINOGENESIS

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

(2010) Jessie Villanueva et al.   CANCER CELL

Glabridin Inhibits Migration, Invasion, and Angiogenesis of Human Non–Small Cell Lung Cancer A549 Cells by Inhibiting the FAK/Rho Signaling Pathway

(2010) Ying-Ming Tsai et al.   INTEGRATIVE CANCER THERAPIES

The Role of Traditional Chinese Herbal Medicines in Cancer Therapy – from TCM Theory to Mechanistic Insights

(2010) W. Hsiao et al.   PLANTA MEDICA

Liver transplantation versus liver resection for the treatment of hepatocellular carcinoma

(2009) Kyung Keun Lee et al.   JOURNAL OF SURGICAL ONCOLOGY

Cell cycle kinases as therapeutic targets for cancer

(2009) Silvia Lapenna et al.   NATURE REVIEWS DRUG DISCOVERY

Recent Developments in Anti-Cancer Agents Targeting the Ras/Raf/ MEK/ERK Pathway

(2009) Kwong-Kwok Wong   Recent Patents on Anti-Cancer Drug Discovery